The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis
- PMID: 19930098
- DOI: 10.1111/j.1365-2796.2009.02167.x
The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis
Abstract
The LDL receptor (LDLR) plays an essential role in the regulation of plasma (LDL) cholesterol concentrations by virtue of its ability to clear plasma LDL. Down-regulation of the LDLR by proprotein convertase subtilisin/kexin 9 (PCSK9) has recently emerged as a regulatory mechanism that controls plasma LDL cholesterol concentrations. Studies in which PCSK9 is over-expressed in mice, have demonstrated that PCSK9, by enhancing hepatic LDLR degradation, decreases the availability of the LDLR for LDL uptake, resulting in increased plasma LDL cholesterol levels. However, PCSK9 has also recently been shown to mediate down-regulation of surface receptors other than the LDLR, suggesting that it may have much broader roles than initially thought.
Similar articles
-
Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation.Circulation. 2013 Jun 18;127(24):2403-13. doi: 10.1161/CIRCULATIONAHA.113.001592. Epub 2013 May 20. Circulation. 2013. PMID: 23690465 Free PMC article.
-
Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.J Am Coll Cardiol. 2013 Oct 15;62(16):1401-8. doi: 10.1016/j.jacc.2013.07.056. Epub 2013 Aug 21. J Am Coll Cardiol. 2013. PMID: 23973703 Review.
-
Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.Arterioscler Thromb Vasc Biol. 2014 Jun;34(6):1171-8. doi: 10.1161/ATVBAHA.113.302670. Epub 2014 Mar 27. Arterioscler Thromb Vasc Biol. 2014. PMID: 24675665
-
Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.Hepatology. 2008 Aug;48(2):646-54. doi: 10.1002/hep.22354. Hepatology. 2008. PMID: 18666258
-
Inhibition of PCSK9 as a novel strategy for the treatment of hypercholesterolemia.Drug News Perspect. 2008 Jul-Aug;21(6):323-30. doi: 10.1358/dnp.2008.21.6.1246795. Drug News Perspect. 2008. PMID: 18836590 Review.
Cited by
-
PCSK9 Biology and Its Role in Atherothrombosis.Int J Mol Sci. 2021 May 30;22(11):5880. doi: 10.3390/ijms22115880. Int J Mol Sci. 2021. PMID: 34070931 Free PMC article. Review.
-
PCSK9 is present in human cerebrospinal fluid and is maintained at remarkably constant concentrations throughout the course of the day.Lipids. 2014 May;49(5):445-55. doi: 10.1007/s11745-014-3895-6. Lipids. 2014. PMID: 24659111
-
Policosanol attenuates statin-induced increases in serum proprotein convertase subtilisin/kexin type 9 when combined with atorvastatin.Evid Based Complement Alternat Med. 2014;2014:926087. doi: 10.1155/2014/926087. Epub 2014 Nov 16. Evid Based Complement Alternat Med. 2014. PMID: 25478000 Free PMC article.
-
Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation.Circulation. 2013 Jun 18;127(24):2403-13. doi: 10.1161/CIRCULATIONAHA.113.001592. Epub 2013 May 20. Circulation. 2013. PMID: 23690465 Free PMC article.
-
LDLR c.415G > A causes familial hypercholesterolemia by weakening LDLR binding to LDL.Lipids Health Dis. 2024 Mar 21;23(1):85. doi: 10.1186/s12944-024-02068-2. Lipids Health Dis. 2024. PMID: 38515137 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous